- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07651839
The Effect of Foot Reflexology in Women With Migraine
The Effect of Foot Reflexology on Pain, Disability, Anxiety, Kinesiophobia, and Postural Control in Women With Migraine
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Karabük Province
-
Karabük, Karabük Province, Türkei (türkiye), 78050
- Karabuk University
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Being a woman between the ages of 18 and 47
- Having been diagnosed with migraine by a neurologist according to the International Headache Society (IHS) criteria
- Volunteering to participate in the study
- Being literate
- Not having entered menopause
Exclusion Criteria:
- Having any neurological disease other than migraine
- Having a psychiatric illness
- Smoking
- Having a musculoskeletal disease affecting the head and neck area
- Having a history of cervical or cranial surgery
- Having irritation or ulceration in the skin area to be massaged
- Receiving migraine treatment other than pharmacological treatment (acupuncture, dry needling, cupping, etc.)
- Having diabetic foot
- Having open wounds on the foot
- Pregnant individuals or individuals who become pregnant during the study period
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Kein Eingriff: control group
The control group will not receive any foot reflexology therapy or other treatment intervention.
|
|
|
Experimental: Migraine group
Before starting foot reflexology treatment, patients will be informed about the treatment process.
The treatment will be performed by a physiotherapist twice a week, with each session lasting 30 minutes, for a total of 10 sessions.
|
Before the treatment program begins, participants will be informed about the treatment procedure. The intervention will be administered by a physiotherapist certified as a Reflexology Practitioner, who has received formal training in reflexology. The treatment will consist of 10 sessions delivered over 5 weeks, with two 30-minute sessions per week. Each session will begin with several passive ankle movements to promote relaxation of the foot and ankle region. Reflexology treatment will be applied first to the right foot and then to the left foot. Target areas on the right foot: Brain, pineal gland, pituitary gland, hypothalamus and thalamus, temples, eye region and optic nerve, ear region, middle ear and balance point, and neck. Additional areas treated on the right foot: Thyroid and parathyroid glands, lungs, liver, facial region, speech center, thymus gland, teeth, diaphragm, vertebral column, and extremities. Areas treated on the left foot: Kidneys, diaphragm, intestines, n |
|
Schein-Komparator: Sham group
superficial massage group
|
The sham group received a superficial massage on the soles of the feet, avoiding targeting reflexology points.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Headache Impact Test (HIT-6)
Zeitfenster: 2 days
|
The Headache Impact Test (HIT-6) is a self-report questionnaire designed to assess the impact of headache on quality of life.
In 2021, Dikmen et al. conducted a study on the reliability and validity of the Turkish version of the Headache Impact Test (HIT-6) in migraine patients.
The test items assess areas such as vitality, pain, and psychological distress, as well as sociability, role, and cognitive functioning.
Three of the six items specifically address the previous four weeks, while the remaining three items do not have a defined time frame.
Each item is answered using a 5-point Likert scale (6=never, 8=rarely, 10=sometimes, 11=very often, 13=always).
The final score is calculated by summing the scores from all six items, ranging from 36 to 78 points.
Impact is categorized on a scale of ≤49 points (very little or no impact), 50-55 points (some impact), 56-59 points (significant impact), and ≥60 points (strong impact), with higher scores indicating a greater impact.
|
2 days
|
|
Migraine Disability Assessment Scale
Zeitfenster: 2 days
|
The Migraine Disability Assessment Scale was used to measure the impact of migraine on a patient's life.
This scale, consisting of 5 questions and 4 disability levels from I to IV (no or little disability, moderate, severe disability), was completed by patients during assessments one week before the injection, and during assessments 4 weeks (+7 days) and 12 weeks (+7 days) after the injection.
Patients were asked questions about their work/school activities.
The total score ranged from 0 to 27.
Scores of 0-5 were classified as Level I, 6-10 as Level II, 11-20 as Level III, and scores above 21 as Level IV.
|
2 days
|
|
International Physical Activity Questionnaire-Short Form
Zeitfenster: 2 days
|
The International Physical Activity Questionnaire - Short Form is a reliable and valid self-report questionnaire developed to assess individuals' levels of physical activity.
Recommended by the World Health Organization, this tool is widely used, particularly in epidemiological studies.
The seven-question questionnaire provides information on time spent walking, moderate-to-vigorous, and vigorous activities.
Time spent sitting is assessed as a separate question.
Scoring involves summing the duration (minutes) and frequency (days) of walking, moderate-to-vigorous activity, and vigorous activity.
A score of "MET-minutes" is obtained from these calculations.
One MET-minute is calculated by multiplying the number of minutes spent on the activity by the MET score.
|
2 days
|
|
Beck Anxiety Scale
Zeitfenster: 2 days
|
The Beck Anxiety Scale (BAS) was developed to measure characteristic anxiety and worry symptoms in patients.
This 21-item scale, with scores ranging from 0 to 63 (higher scores indicating severe anxiety), was completed by patients during assessments one week before the injection, and again four weeks (+7 days) and twelve weeks (+7 days) after the injection.
The control group completed the scale once.
For each item, patients selected one of the following options: 0 = none, 1 = mild, 2 = moderate, and 3 = severe, resulting in a total score ranging from 0 to 63. Scores of 0-7 were considered normal, 8-15 mild, 16-25 moderate, and 26-63 severe.
|
2 days
|
|
Assessment of postural control
Zeitfenster: 2 days
|
Postural balance will be assessed using a device that measures body sway by sensing foot pressure.
The platform on the device detects body sways.
The platform consists of a hard surface, but a soft surface can be achieved by placing a foam cushion on it.
The platform must be placed on a flat surface so that it does not move.
Through the platform, the individual's center of pressure is visualized, and oscillations occurring in the anteroposterior (AP) and mediolateral (ML) directions can be monitored.
Changes occurring on the platform are displayed on a computer screen using Bertec Workbook software.
|
2 days
|
|
Tampa Kinesiophobia Scale
Zeitfenster: 2 days
|
The Tampa Kinesiophobia Scale (TMS) is a self-report scale developed to assess individuals' levels of avoidance of movement due to fear of pain or re-injury.
Kinesiophobia is a significant psychological factor, particularly prevalent in individuals with chronic pain, and can lead to functional limitations by restricting participation in physical activity.
The TMS consists of 17 items and is scored using a 4-point Likert scale; higher scores indicate a high level of fear of movement.
The Turkish validity and reliability study was conducted by Yılmaz et al., and the scale is widely used in clinical and research settings.
|
2 days
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Neurologische Manifestationen
- Erkrankungen des Gehirns
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Psychische Störungen
- Kopfschmerzerkrankungen, primär
- Kopfschmerzen
- Phobische Störungen
- Pathologische Zustände, Anzeichen und Symptome
- Anzeichen und Symptome
- Kinesiophobie
- Schmerzen
- Angststörungen
- Migräneerkrankungen
Andere Studien-ID-Nummern
- KBU-FTR-NC-10
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .